News Posts List
GeoVax Labs, Inc. (OTCQB: GOVXD), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2019 and provided an update on its corporate development progress.
Ethicon, a subsidiary of Johnson & Johnson (J&J), has agreed to acquire TachoSil Fibrin Sealant Patch from Takeda for $400m upfront in cash. Novartis has also agreed to acquire dry eye drug Xiidra from Takeda for $3.4bn upfront in cash. Takeda plans to use the proceeds from these divestitures to decrease its debt and enhance deleveraging toward its target of 2.0x net debt/adjusted EBITDA in the medium term. TachoSil is a ready-to-use surgical patch developed to help surgeons to achieve fast and reliable bleeding control and tissue sealing.
TOKYO/ZURICH (Reuters) - Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.
National Institutes of Health Awards Moonlight Therapeutics with a $2.5 Million Grant to Advance Development of Peanut Allergy Treatment
Funding to support company’s preclinical development of a breakthrough allergy treatment Moonlight Therapeutics, Inc., a biotechnology company developing treatments for food allergies, announced today the receipt of $2.5 million in funding for preclinical studies and product development that will enable preparations for a clinical trial for its lead program in peanut allergy. This funding was awarded through a highly competitive Small Business Technology Transfer (STTR) Fast Track grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). Moonlight’s proprietary platform, TASIS — Targeted Allergen-Specific Immunotherapy within the Skin — involves the application of a small, minimally invasive dermal stamp that uses microneedles to target the delivery of allergens to the skin’s immune cells. The stamp is removed within a few minutes and the administration is complete.
Emory University is planning a $475 million cancer tower at Emory University Hospital Midtown. The new cancer tower at 550 Peachtree Street would be 17 stories and be located on the north side of the EUHM campus and connected to the existing hospital, according to plans filed with the Georgia Department of Community Health. The tower will consist of approximately 455,000 square feet of new construction and will include about 64 inpatient beds and 26 observation beds. "The tower will also include research space, perioperative services, imaging services, radiation oncology, a clinical laboratory, pharmacy, infusion therapy and outpatient clinic space. In addition, an array of support services will located in the new tower," Emory says.
Skyhawk signed its third major deal in a year, this time with Takeda. Like its first two partnerships, the focus will be in neurology, but Skyhawk is in discussions with companies that could help extend its platform to other areas. On Tuesday, Skyhawk Therapeutics Inc. (Waltham, Mass.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive worldwide rights to therapies against multiple targets for undisclosed neurodegenerative diseases. Skyhawk will be responsible for discovery and preclinical development using its SkySTAR platform, after which Takeda will take over the programs. Financial details are undisclosed.
Emory University plans a $1 billion, 15-year-plus development of a new "health innovation district" on North Druid Hills Road at Interstate 85. In 2016, Emory bought about 60 acres in Executive Park, directly across North Druid Hills Road from where Children's Healthcare of Atlanta is now developing a $1.5 billion hospital campus. On May 1, Emory filed a rezoning application with the city of Brookhaven in which it envisions a mixed-use development on the property with office, medical services, a hospital, commercial space, a hotel and multifamily. Emory says it seeks to replace the retail and office developments now on the property with a development "that builds on the successful programs in orthopedics, sports medicine, brain health, medical science education and health information technology already located on the site."
Takeda Pharmaceutical has advanced further into gene editing, inking a licensing option agreement with and, through its venture capital arm, investing in Emendo Biotherapeutics, the gene editing discovery platform developer said today. The value of the agreement and the investment were not disclosed. Through the licensing option agreement, Emendo has granted Takeda the option to use its proprietary nuclease program OMNI to edit two genes as part of the pharma’s R&D efforts to treat unspecified genetic disorders.
Augusta University Medical Center is moving forward with plans to construct a new hospital and medical campus on Interstate 20 in Columbia County, Ga., 13 miles west of downtown Augusta. AU Medical Center on April 19 filed plans with the state of Georgia for the project as a development of regional impact. Plans call for a medical mixed-use campus consisting of an approximately 600,000-square-foot hospital with associated uses, approximately 125,000 square feet of medical office buildings, and approximately 60,000 square feet of professional, health, and retail uses. Earlier in April, AU Medical Center filed to rezone the 52-acre site of the proposed medical campus. Check out a site plan here. The project is being designed by Catalyst Design Group of Nashville, Tenn.
CDMO Recro Gainesville will continue to supply Verapamil SR capsules through 2024 Recro Gainesville, the contract development and manufacturing organization (CDMO) division of Recro Pharma, has amended its existing license and supply agreement with Teva Pharmaceutical to extend the agreement for six years, effective January 1, 2019. Under the terms of the amended agreement, Recro Gainesville will continue to supply Teva with Verapamil SR capsules through 2024 and Teva will continue to be Recro Gainesville’s exclusive U.S. distributor of the product, for which Recro Gainesville is the New Drug Application (NDA) holder. The 2019 Teva agreement provides to Recro Gainesville the same revenue economics as the original agreement, including both manufacturing and profit sharing components. Prior to this amendment, the license and supply agreement with Teva for Verapamil SR was renewable on a year-to-year basis.
|Neon CRM by Neon One